Revises MBXP financials, takes SEK 43m loss MBXP earnout reduced from SEK 125m to zero, lifts net ca...
Redeye finds that the clinical study of fostrox in liver cancer is progressing favourably with some ...
Redeye returns with an update on Bredband2's acquisition of Stockholm Stadsnät AB with a positive vi...
Redeye adjusts its estimates and valuation following the SEK425m directed share issue and the acquis...
We include Stockholms Stadsnät AB into our forecasts.
Scandinavian Astor Group (”Astor Group” eller ”bolaget”) meddelade den 15 december att dotterbolaget...
Redeye endorses SenzaGen’s new order from a global biotech industry leader.
Sprint Bioscience (Sprint) meddelar att Deciphera har valt att returnera VPS34-hämmarprogrammet utan...
This morning, Bredband2 announced the acquisition of Stockholm Stadsnät AB with 40 thousand customer...
Primärt mål uppnått Vid en utökad analys, av de åtta patienter med misstänkt endometrios som deltog ...
Mangold uppdaterar investmentbolaget Capsek. De onoterade innehaven som är i en tidig fas (scale-up)...
This Tuesday, between 15:00-18:00, Egetis Therapeutics hosts a Capital Markets Day.
Redeye comments on Arise’s acquisition of Fenix Repower AS, a Norwegian project developer active in ...
Acquires Svensk Direktreklam for SEK 350m (fully paid in cash).
SpagoPix (earlier SN132D, now pegfosimer manganese) was compared with ultrasound and traditional MRI...
Biovica’s right issue secures SEK 100m, and the number of shares will increase from 45.
Qbrick meddelade den 14 december att bolagets dotterbolag Ritualen har slutfört leverans av det hitt...
Vitrolife’s CEO Bronwyn Brophy came across as executive and resourceful during her first CMD at Vitr...
Well-run company with proven ability... ...to adapt to changing demand environment In good shape for...
Redeye comments on ADVANCE II’s principal investigator presenting an ADVANCE II survival update at A...
